Pneumocystis jirovecii pneumonia (PJP) is life-threatening for immunocompromised patients. No consensus exists on PJP prophylaxis for immunosuppressed patients without HIV, transplant, or cancer.

Timely diagnosis, treatment, and delays in systemic lupus erythematosus (SLE) remain underexplored in the Central America and Caribbean (CAC) region. The objective was to describe and analyze patient-level and health care system-level barriers and facilitators associated with diagnostic and therapeutic delays in SLE, based on experiences of patients and rheumatologists from 6 countries in the CAC region.

This study aimed to investigate the impact of clinical and psychological factors on the discordance between patient and physician global assessments (PGA and PhGA) in patients with psoriatic arthritis (PsA).

Self-reported allergies to penicillin and other beta-lactam antibiotics pose a public health challenge due to their association with broad-spectrum antibiotic overuse, increased health care costs and worse clinical outcomes. Of the general population, 10% to 25% are labeled as beta-lactam allergic, but fewer than 1% have beta-lactam antibiotic allergies as confirmed by testing. Patients with systemic autoimmune rheumatologic diseases (SARDs) may be more likely to be labeled, but little is known about beta-lactam allergy in this population. This scoping review characterizes (1) reported prevalence, (2) possible shared etiopathogenesis, (3) de-labeling strategies, and (4) clinical implications of beta-lactam allergy in SARDs.

Osteoporosis is common in dialysis patients, yet treatment options are limited due to safety concerns in advanced kidney disease. Denosumab, with non-renal clearance, has been increasingly used, but its cardiovascular safety remains uncertain.

Systemic vasculitides are inflammatory diseases affecting multiple organs and impacting patients' quality of life, including sexual health-an aspect often overlooked in clinical care. This study aimed to identify factors associated with SD in patients with systemic vasculitis.

Ascites is a rare but potentially severe manifestation of systemic lupus erythematosus (SLE). We investigated the clinical characteristics and treatment outcomes, including recurrence of ascites, in patients with SLE.

The delay in managing patients with juvenile systemic lupus erythematosus (jSLE) is one of the most important determinants impacting outcomes.

Canakinumab (CAN), a monoclonal antibody targeting interleukin-1β, has demonstrated efficacy in various autoinflammatory diseases (AIDs), particularly in inadequate response to colchicine in familial Mediterranean fever (FMF). This study aimed to evaluate the indications, efficacy, and safety of CAN based on real-life experience from a tertiary rheumatology clinic.

Cytomegalovirus (CMV) infection is prevalent in patients with anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis (MDA5+DM) and affects the prognosis. This study aimed to evaluate the efficacy of valganciclovir prophylaxis during MDA5+DM treatment.

Relapses occur in 14% to 44% of patients with antineutrophil cytoplasm antibody-associated vasculitis (AAV). The French Vasculitis Study Group Relapse Score (FRS) was recently proposed to predict relapse risk. This study aimed to identify relapse-associated factors and evaluate the FRS performance in a Mexican cohort.

Nintedanib, a tyrosine kinase inhibitor with antifibrotic properties, has been shown to significantly slow the progression of pulmonary fibrosis. The aim of this study is to assess the clinical characteristics, longitudinal pulmonary function tests, serial high-resolution computed tomography (HRCT) findings, and the efficacy, tolerability, and outcomes of nintedanib treatment in patients with systemic autoimmune rheumatic disease-associated interstitial lung disease (SARD-ILD) within a Middle Eastern population.

Pegloticase is indicated to lower serum urate (SU) in patients with uncontrolled gout refractory to urate-lowering therapy. Pegloticase is infused for 120 minutes every 2 weeks, which can create logistical barriers. The phase 4, open-label AGILE trial (NCT04511702) assessed the safety and efficacy of shorter-duration pegloticase infusions in patients with uncontrolled gout.